

LIST OF FIGURES

Figure	Page
1. Schematic design of HCV	1
2. Genome of HCV	2
3. HCV life cycle	4
4. Components of antiviral immune response to HCV	6
5. Changes in the hepatic architecture due to fibrosis	9
6. Mechanisms of hepatic fibrogenesis and possible molecular serum biomarkers	9
7. Structure of an HIV viron particle	31
8. The viral genome for HIV-1	31
9. Progression of HIV-1 infection	35
10. Structure of HA	38
11. Serum hyaluronic acid ELSA kit.	43
12. Typical standard curve for HA ELISA	45
13. Comparison between groups regarding to patient's age	50
14. Comparison between groups regarding patients gender	51
15. Comparison between groups regarding risk of acquiring infection	53
16. Comparison between groups regarding to type of risk	54
17. Comparison between groups as regard to patient's symptoms	56
18. Comparison between groups as regard to patient's clinical signs	58
19. Comparison between groups as regard to patient's Hb	60
20. Comparison between groups as regard to patient's platelets	60
21. Comparison between groups as regard to ALT	64
22. Comparison between groups as regard to AST	64
23. Comparison between groups as regard to ALP	65
24. Comparison between groups as regard to Prothrombin activity(%)	65
25. Comparison between groups as regard to total bilirubin	66
26. Comparison between groups as regard to direct bilirubin	66
27. Comparison between groups as regard to Serum albumin	67
28. Comparison between group I patients as regard to liver biopsy	68
29. Comparison between groups as regard to serum hyaluronic acid (HA)	69

30. Comparison between groups as regard to Ultrasound finding	70
31. Correlation between serum hyaluronic acid (HA) and ALT	73
32. Correlation between serum hyaluronic acid (HA) and AST	73
33. Correlation between serum hyaluronic acid (HA) and Albumin	74
34. Correlation between serum hyaluronic acid (HA) and prothrombin activity	74
35. Correlation between serum hyaluronic acid (HA) and total bilirubin	75
36. Correlation between serum hyaluronic acid (HA) and direct bilirubin	75
37. Correlation between serum hyaluronic acid (HA) and fibrosis in group Ia	76
38. Correlation between serum hyaluronic acid (HA) and fibrosis in group (Ib)	77
39. Correlation between serum hyaluronic acid (HA) and fibrosis in group (I)	77
40. Correlation between serum hyaluronic acid (HA) and Ultra sound Finding	78

LIST OF ABBREVIATIONS

AASLD	American Association for the Study of Liver Diseases
AIDS	Acquired Immunodeficiency Syndrome
ALP	Alkaline phosphatase
ALT	alanine aminotransferase
ANA	Anti nuclear antibodies
APRI	AST to platlet ratio index
AST	Aspertate aminotransferase
BBSS	Biological/behavioral surveillance survey
CDC	Center of disease control and prevention
CHC	Chronic Hepatitis C
CIA	Chemiluminescence Immunoassay
COPD	Chronic Obstructive Pulmonary Disease
CRAs	Chemokine receptor antagonists
CT	Computed tomography
CTGF	Connective tissue growth factor
CTL	Cytotoxic T Lymphocytes
DAAs	Direct-acting antiviral agents
DNA	Deoxyribonucleic acid
E	Envelop
ECM	Extra Cellular Matrix
EIAs	Enzyme Immunoassays
ELISA	Enzyme Linked Immunosorbent Assay
ESLD	End stage liver disease
ETR	End-of-treatment response
EVR	Early Virological Response
FDA	Food and Drug Administration
FIs	Fusion inhibitors
Gal C	Galactosyl ceramide
GGT	gamma glutamyl transferase
gp	Glycoprotein
H&E	Heamatoxylin and eosin
HA	Hyaluronic Acid
HAART	Highly active antiretroviral therapy
HAI	Histologic activity index
HBsAg	Hepatitis B surface antigen
HBV	Hepatitis B Virus

HCC	Hepatocellular Carcinoma
HCV	Hepatitis C Virus
HIV	Human Immunodeficiency Virus
HRP	Horseradish Peroxidase
HSCs	Hepatic Stellate Cells
HVR	Hyper Variable Region
IDU	Intravenous Drug Use
IDUs	Injecting drug users
IFN	Interferon
IFNAR	Interferon alfa receptor
IFNGR	Interferon gamma receptor
IIs	Integrase inhibitors
IL-2	Interleukin 2
ISDA	Infectious Disease Society of America
kDa	Kilodalton
MALT	Mucosal –associated lymphoid tissue
MHC	Major Histocompatibility Complex
MMPs	Matrix Metalloproteinases
MPGN	Membranoproliferative Glomerulonephritis
MRI	Magnetic resonance imaging
MSM	Men having sex with men
MT1-MMP	membrane type matrix metaloproteinase 1
NK-cell	Natural Killer cell
NNRTIs	Non nucleoside reverse transcriptase inhibitors
NPV	Negative predicted value
NRTIs	Nucleoside reverse transcriptase inhibitors
NS	Non Structural
O.D	Optical denesity
ORF	Open Reading Frame
P4NP	Procollagen IV N-terminal peptid
P-C	Portal to central
PDGF	Platelet derived growth factor
PEG	Polyethylene glycol
PEG-IFN	Pegylated Interferon
PIIINP	Procollagen III N-terminal peptid
PINP	Procollagen I N-terminal peptid
PIs	protease inhibitors

P-P	Portal to portal
PT	Prothrombin
RBV	Ribavirin
RIBA	Recombinant immunoblot assay
RNA	Ribonucleic acid
ROC	Receiver operating curve
ROS	Reactive Oxygen Species
RT-PCR	Reverse Transcriptase Polymerase Chain reaction
RVR	Rapid Virological Response
SMV	Simiprevir
SOF	Sofosbuvir
SS	Sjogren's Syndrome
STIs	Sexually transmitted infections
SVR	Sustained Virologic Response
TE	Transient Elastography
TGF-β	Transforming Growth Factor β
Th cells	Helper T Cells
TIMPs	Tissue inhibitors of Matrix Metalloproteinases
TMA	Transcription-Mediated Amplification
TSH	Thyroid stimulating hormone
U.S.	United States
US	Ultrasonography
UTR	Untranslated Region
UV	Ultra violet
VL	Viral load
Vs	Versus